Idi is the Head of Mass Spectrometry GBI, EIT Oxford. His research is centred on advancing mass spectrometry (MS) technologies, with a particular focus on their integration into generative biology and drug discovery. His group is actively developing next-generation MS platforms to interrogate complex biomolecular systems.

Previously, Idi co-founded OMass Therapeutics and served as Senior Director of Technology and CTO. At OMass, he led the development and biotech translation of innovative native MS-based methodologies for drug discovery. His work was instrumental in building the company from inception, guiding its technological strategy, fund raising  and enabling the progression of programs into clinic.

Idi holds a Master’s degree in Chemistry from ETH Zurich and completed his DPhil in Chemistry at the University of Oxford. His academic and industry contributions span the interface of analytical chemistry, structural biology, and translational drug development.

‍